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Abstract
The measures, definitions, and processes
used in the Smoke-Free Families clinical
trials to assure consistent measurement
and reporting of various aspects of the tri-
als are described. Definitions of current
smokers at diVerent points in the
pregnancy, levels of addiction, biological
verification, cessation, stages of change,
and intervention approaches are pre-
sented along with the rationale underlying
their adoption and development.
(Tobacco Control 2000;9(Suppl III):iii87–iii90)
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The purpose of the Smoke Free Families
(SFF) project is to identify innovative best
practices for achieving smoking cessation
before, during, and after pregnancy. Eleven
clinical trials were undertaken with a wide
variety of promising interventions. To assure
consistency across all of the trials and to facili-
tate meta-analysis of the results from these tri-
als, the Smoke Free Families National
Program OYce (NPO) and the Centers for
Disease Control and Prevention (CDC)
defined common measures and processes to be
applied across all projects. This paper presents
these measures and processes.
Methods
The literature on smoking cessation during
pregnancy was reviewed to identify measures
used for assessment of smoking status in the
prenatal, preconceptional, and postpartum
periods, biochemical verification of smoking
status, determination of cessation, definition of
the stages of pregnancy quitting, and
documentation of the implementation of the
intervention, including provider time. A work-
ing group met in September of 1995 to review
the material and to achieve consensus on the
most useful measures. The group was
established by the CDC and SFF with
membership from the American Cancer
Society, the CDC, the Robert Wood Johnson
Foundation, SFF NPO, SFF National
Advisory Committee (NAC), SFF grantees,
and invited experts. Comments from all SFF
grantees were solicited and modifications to
the measures were made as appropriate. Guid-
ance for all SFF grantees was then distributed
in advance of trial initiation.
Assessment of smoking status
Questions were chosen, adapted or developed
to assess smoking status at two diVerent points
in time: (1) at the time of the first prenatal visit
(prenatal screening), including questions about
smoking before pregnancy (preconceptional);
and (2) at some specified time following the
end of pregnancy (postpartum screening). The
questions listed in box 1 were used for prenatal
assessments and, in box 2, for postpartum
assessments.
PRENATAL SCREENING
The purpose of the prenatal screening
questions is to identify pregnant smokers at the
time they enter prenatal care. Accurate assess-
ment of smoking status at the first prenatal visit
identifies smokers for participation in the trial
and establishes a baseline measure of smoking
status for each enrolled participant and of
smoking prevalence for the study population.
Some studies also used these questions in sub-
sequent assessments of smoking status, as
specified by the trial protocol. All trials, at a
minimum, were required to ask these questions
at the first prenatal visit. A second assessment
was required at or near the end of pregnancy to
establish changes in smoking status during the
pregnancy. The timing of the postpartum
assessment varied with the study design. The
suggested order of these questions was based
on current knowledge of approaches to
minimise non-disclosure of smoking status.1
MEASURES OF CURRENT SMOKING STATUS
At least two, and as many as four, questions
about current smoking status were asked of the
pregnant woman during her first prenatal visit
(box 1).
Responses to questions 1, 2, and 3 allowed
each woman to be categorised as a “smoker” or
a “non-smoker”. Question 1 is designed to
minimise non-disclosure of smoking status and
to provide investigators more specific informa-
tion about current smoking behaviour. Many
pregnant women are reluctant to disclose their
smoking status at the first prenatal visit.
Deception rates as high as 23% among Medic-
aid insured1 2 and 14% among privately
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insured pregnant women3 have been biochemi-
cally confirmed. Non-disclosure can be
reduced using a multiple choice question as
compared to a simple “yes-no” question.3 The
multiple choice question tested by Mullen was
modified slightly by the working group and is
used as the initial screening question (box 1,
question 1).
A woman was not classified as a smoker
based only on her response to question 1. She
was also asked question 2 (box 1). If she indi-
cated smoking, even a puV, within the previous
30 days, she was then asked question 3 to
determine if she had smoked, even a puV,
within the previous seven days. This question is
frequently used to determine if a person is cur-
rently smoking.4 The answer of “yes” to
question 3 and of “a”, “b” or “c” to question 1
resulted in the classification of the pregnant
woman as a “smoker”. At this point, she was
given an opportunity to enroll in the smoking
cessation program. If she chose response “d”,
“e” or “f” to question 1 and answered “no” to
question 2, she was considered a “non-
smoker” by self report.
Questions 4 and 5 were optional questions to
be asked of pregnant smokers. They were used
to measure the level of addiction based on the
quantity of cigarettes smoked during a typical
day and the timing of the first cigarette of the
day.4 Question 5 may need to be adjusted for
special populations such as teens who may not
be in situations that let them behave as they
would in unsupervised situations. For example,
teens may postpone their first cigarette of the
day in instances where they live at home and
want to avoid smoking in front of their parents.
BIOCHEMICAL VERIFICATION OF SELF REPORTS
(OPTIONAL)
If possible, biochemical verification of self
reported smoking status was done at the time
the other questions were asked (box 1, item 6).
Baseline biochemical verification is essential in
studies that have a major intervention goal of
significantly reducing cigarette consumption
by pregnant smokers. Investigators were asked
to report exactly when, in relation to the asking
of the prenatal screening questions, they
informed the pregnant woman that biochemi-
cal verification of her smoking status was being
undertaken.
Measures and tests that could be used by
investigators to confirm self reports include
urinary or saliva cotinine and expired carbon
monoxide. The cut oV level for determining
active, rather than passive, exposure to
cigarette smoke for urinary cotinine is > 80 ng/
ml, for saliva cotinine is > 30 ng/ml, and for
expired carbon monoxide is > 9 parts per
million.5 6 Creatinine adjustment of urinary
cotinine is not necessary when defining smok-
ing status for a population of pregnant women,
since adjustments do not aVect classification of
women as smokers or quitters. However, in
studies of reduction, or in dealing with
individual women, creatinine adjustments may
be necessary, especially for women who smoke
very little or may only have passive exposure.
Baseline cotinine concentrations have been
shown to vary by race, with higher cotinine
concentrations observed in black rather than in
white smokers. These diVerences are
significant and are not explained by reporting
bias or nicotine intake diVerence. However,
these diVerences do not aVect choice of cut oV
values for determining active smoking.7
MEASURES OF PRECONCEPTIONAL SMOKING
STATUS (OPTIONAL)
The preconceptional questions were used to
obtain information about the pregnant
Box 1. Recommended questions for prenatal screening
1. Current smoking status
Which statement best describes you now?
a. I smoke regularly now—about the same amount as BEFORE I
found out I was pregnant.
b. I smoke regularly now, but more than BEFORE I found out I
was pregnant.
c. I smoke some now, but I have cut down SINCE I got pregnant.
d. I stopped smoking AFTER I found out I was pregnant, and I
am not smoking now.
e. I stopped smoking BEFORE I found out I was pregnant, and I
am not smoking now.
f. I have NEVER smoked more than 100 cigarettes.
2. Current smoking status
Have you had a cigarette, even a puV, within the last 30 days?
a. Yes b. No
3. Current smoking status
Have you had a cigarette, even a puV, within the last 7 days?
a. Yes b. No
4. Current smoking quantity (optional)
During the past 7 days, how many cigarettes or packs of cigarettes
did you smoke on an average day? (A pack has 20 cigarettes)
__cigarettes or __packs ( ) Less than 1 cig/day ( ) Didn’t
smoke ( ) Don’t know
5. Addiction measure (optional)
How soon after you wake up do you usually smoke your first ciga-
rette?
__Immediately __minutes (number) __Hours (number)
__No usual time/time varies __Don’t know
6. Baseline biochemical measurements (optional)
7. Preconceptional smoking status
In the past 3 months before you got pregnant, how many
cigarettes or packs of cigarettes did you smoke on an average day?
(A pack has 20 cigarettes)
__cigarettes or __packs ( ) less than 1 cig/day ( ) Didn’t smoke
( ) Don’t know
Box 2. Recommended supplementary questions for
postpartum screening
8. Current smoking status
Did you smoke cigarettes at all during the 12 months before your
delivery?
( )Yes—Go to next question ( )No
9. Smoking status during pregnancy
In the 3 months after you got pregnant, how many cigarettes or
packs of cigarettes did you smoke on an average day? (A pack has
20 cigarettes)
__cigarettes or __packs ( ) Less than 1 cig/day ( ) Didn’t smoke
( ) Don’t know
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woman’s smoking status and level of addiction
in the three months before conception. In most
cases these questions are asked retrospectively
of women who are just beginning their prenatal
care.
Two questions were suggested but not
required. The first, question 7, was taken from
the pregnancy risk assessment monitoring sys-
tem (PRAMS), an ongoing, state specific,
population based surveillance system designed
to identify and monitor selected maternal
behaviours and experiences before, during,
and after pregnancy.8 Responses to this
question allow researchers to estimate the
prevalence of self reported smoking among the
study population before pregnancy and to cat-
egorise smokers on the basis of the quantity
smoked. These measures can then be used with
other indicators to identify spontaneous
quitters and to observe self reported reductions
in the numbers of cigarettes smoked.
It was also suggested that question 5 be
modified to assess level of addiction before
pregnancy rather than level of addiction at the
current time as specified in the questions for
the prenatal assessment of smoking status.
POSTPARTUM SCREENING
The postpartum screening questions are used
to identify current smokers during the postpar-
tum period and to assess smoking behaviours
before and during pregnancy. As presented
here, they are intended for use in studies where
enrollment occurs only at the postpartum visit.
Prenatal screening questions 3, 4, and 5 (box
1) are suggested for postpartum assessments
along with questions 8 and 9 (box 2).
Questions 3, 4, and 5 are used to determine
current smoking status, quantity smoked, and
level of addiction at the postpartum visit.
Women were classified as smokers if they indi-
cated smoking a cigarette, even a puV, within
the last seven days. Question 8 provides a self
report of smoking during the pregnancy, and
question 9 of quantity smoked during the first
three months of pregnancy.
Biochemical verification of self reported
smoking status is also suggested for
postpartum assessments.
DEFINITION OF CESSATION
The measure of success for the SFF trials was
biochemically verified cessation. The process
and questions described below were used to
identify pregnant smokers who quit smoking
cigarettes.
+ Quit: A pregnant smoker could be classified
as a quitter only if the following conditions
were met: (1)The pregnant smoker must
report cessation by answering “no” to the
question “Have you had a cigarette, even a
puV, in the last 7 days?” (Question 3, Box
1); and (2) there must be a biochemical
verification of her smoking status indicating
that she has not smoked within the period
covered by the biochemical marker in use.
+ Timing of quit (optional): The following
question was suggested to ascertain the tim-
ing of cessation, especially if the study
focused on an outcome in which documen-
tation of total smoking exposure during
pregnancy could be important:
When did you smoke your last cigarette?
_____/_____/____ (month/day/year)
+ Relapse (optional): This question was
suggested to determine if the pregnant
woman relapsed at all since her most recent
cessation attempt. It is especially important
in studies using stage tailored counselling:
Have you smoked at all, even a puV, since
you last quit? ( ) Yes ( ) No
+ Quit attempts before and after pregnancy
(optional): The following questions were
developed by the working group to assess
the cycling of quitting and its relevance to
the pregnant woman’s ability to quit:
(a) How many times had you quit smoking
for more than 24 hours before you found
out about this pregnancy?
____None _____Times ____Don’t know
(b) How many times have you quit smoking
for more than 24 hours since you found
out about this pregnancy?
____None _____Times ____Don’t know
STAGING PREGNANCY QUITTING
For those trials using stage tailored behavioural
interventions, standard questions were used to
determine the stage of readiness for each preg-
nant smoker. Smokers were classified as being
in one of four stages: precontemplation,
contemplation, preparation or action, based on
their responses to the questions in box 3. The
stage assessments occurred at enrollment and
at postpartum follow up as well as at selected
intervals between these two points. Interim
measurements may not have been necessary or
helpful for some intervention designs.
DOCUMENTATION OF INTERVENTION
Documentation of the various components of
the intervention and of how it is implemented
is critically important when evaluating
program performance and/or considering
replication of the program. To assure that pro-
grams could be adequately described and that
program fidelity had been achieved in the trial,
the following information was required and
collected for each intervention:
+ A thorough description of program com-
ponents, methods and training
+ Documentation of the type, content and
distribution schedule of self help materi-
als provided to smokers
+ Descriptions of the pregnant smokers’
use and ratings of self help materials pro-
vided to them
Box 3. Staging pregnancy quitting
10. Have you smoked any cigarettes in the past 7 days, even a puV?
Yes—Go to next question No= Action
11. If yes, are you seriously thinking about quitting completely
during this pregnancy?
Yes—Go to next question No= Precontemplation
12. If yes, are you planning to quit completely in the next 30 days?
Yes = Preparation No = Contemplation
Smoking cessation intervention research iii89
www.tobaccocontrol.com
+ Documentation of the pregnant smoker’s
compliance with intervention proto-
col(s), including their use of various
methods and materials
+ Documentation of the data management
process for assuring accuracy in data col-
lection
DOCUMENTATION OF PROVIDER TIME SPENT
IMPLEMENTING INTERVENTIONS
Given the significant time constraints faced by
providers, it is important to document the time
required to deliver interventions. A set of ques-
tions was developed by the working group to
document: (1) how much of each type of pro-
vider’s time it actually took to implement a
particular prenatal smoking cessation interven-
tion; and (2) the sequencing of the intervention
in relation to other activities occurring during
the visit. Answers to these questions are impor-
tant for purposes of quality assurance, clinic
eYciency, and cost estimation as well as for
future replication eVorts.
Documentation of the following compo-
nents was suggested but not required:
+ Description of the particular component
of the intervention being delivered by
each provider
+ Description of the content and method
used in implementing each intervention
component
+ Documentation of the amount of time
actually spent with the pregnant woman
by each provider and the content of each
interaction
+ Description of the type of provider (for
example, level of experience, training)
implementing each component of the
intervention
+ Salary range for each type of provider
Conclusion
In the mid 1980s, a review of the literature on
smoking cessation treatments for pregnant
women resulted in a call for utilising scientific
criteria for rigorous, valid research into ways to
educate the pregnant smoker.9 When the SFF
trials began in 1995, only a few approaches had
been rigorously evaluated and did not, either
collectively or individually, point the way for
evidence based practice for smoking cessation
treatments for pregnant women. The SFF
trials were designed, in part, to address this
need for rigorous studies with clear
implications for practice. They were also
designed to be consistent in their definitions,
measures, and processes. Definitions of current
smokers at diVerent points in the pregnancy
and following it, levels of addiction, biological
verification, cessation, stages of change, and
intervention approaches created a template for
the exchange of information and participation
in subsequent meta-analyses. Rigorous and
consistently applied processes and measures
allowed the SFF investigators to meet the
standards required for developing the most
defensible evidence of intervention eYcacy
and for increasing the likelihood that findings
from these trials would be useful in developing
eVective treatments for pregnant smokers.
While this information should be helpful to
researchers in understanding and interpreting
SFF findings, it may also serve as a useful con-
struct for future work in this area. New
approaches to some of the assessments used
here are currently being explored. For
example, new approaches to asking women
about their smoking status were recently
reported.10 As refinements and enhancements
are made, they should be systematically incor-
porated into future eVorts to evaluate the
eVectiveness of cessation treatments for
pregnant women.
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